Core Viewpoint - The company has successfully administered its first self-developed radiopharmaceutical drug, 177Lu-PSMA-3D1015 (3D1015), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research - The study focuses on evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive mCRPC [1] - The research aims to systematically assess the core clinical value of 3D1015, emphasizing drug safety and dosimetry evaluation [1] - The study will collect in-depth pharmacokinetic characteristics and dose exploration data to provide direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]
思路迪医药股份(01244)：新型放射性核素偶联药物3D1015首次人体给药成功